PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
- First Online:
- Cite this article as:
- Kysenius, K., Muggalla, P., Mätlik, K. et al. Cell. Mol. Life Sci. (2012) 69: 1903. doi:10.1007/s00018-012-0977-6
- 1.1k Views
The secreted protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipid (LDL) receptor family members LDLR, very low density lipoprotein receptor (VLDLR) and apolipoprotein receptor 2 (ApoER2), and promotes their degradation in intracellular acidic compartments. In the liver, LDLR is a major controller of blood LDL levels, whereas VLDLR and ApoER2 in the brain mediate Reelin signaling, a critical pathway for proper development of the nervous system. Expression level of PCSK9 in the brain is highest in the cerebellum during perinatal development, but is also increased in the adult brain after ischemia. The mechanism of PCSK9 function and its involvement in neuronal apoptosis is poorly understood. We show here that RNAi-mediated knockdown of PCSK9 significantly reduced the death of potassium-deprived cerebellar granule neurons (CGN), as shown by reduced levels of nuclear phosphorylated c-Jun and activated caspase-3, as well as condensed apoptotic nuclei. ApoER2 protein levels were increased in PCSK9 RNAi cells. Knockdown of ApoER2 but not of VLDLR was sufficient to reverse the protection provided by PCSK9 RNAi, suggesting that proapoptotic signaling of PCSK9 is mediated by altered ApoER2 function. Pharmacological inhibition of signaling pathways associated with lipoprotein receptors suggested that PCSK9 regulates neuronal apoptosis independently of NMDA receptor function but in concert with ERK and JNK signaling pathways. PCSK9 RNAi also reduced staurosporine-induced CGN apoptosis and axonal degeneration in the nerve growth factor-deprived dorsal root ganglion neurons. We conclude that PCSK9 potentiates neuronal apoptosis via modulation of ApoER2 levels and related anti-apoptotic signaling pathways.
Apolipoprotein receptor 2
Cerebellar granule neuron
Dorsal root ganglion neuron
Human umbilical vein endothelial cell
c-Jun N-terminal kinase
Low density lipid
Low density lipoprotein receptor
Mitogen-activated protein kinase
Nuclear factor kappa-light-chain-enhancer of activated B cells
Nerve growth factor
Proprotein convertase subtilisin/kexin type 9
Src family kinase
Short hairpin RNA
Very low density lipoprotein receptor
Neuronal apoptosis is crucial for proper development of the nervous system, and after neuronal trauma, proapoptotic mechanisms cause damage to neuronal network integrity . Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) , with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3, 4]. Unlike the other PCs, the proteolytic function of PCSK9 is auto-inhibited by non-covalent binding of the pro-domain to the catalytic site . PCSK9 binds to the extracellular EGF-A repeat of low-density lipid receptor family members low-density lipoprotein receptor (LDLR), very low-density lipoprotein receptor (VLDLR), and apolipoprotein receptor-2 (ApoER2) [6, 7], and targets them for degradation in the intracellular acidic compartments . Gain- and loss-of-function mutants of PCSK9 are associated with hyper- and hypocholesterolemia, respectively, by affecting systemic levels of LDLR and cholesterol uptake . There are controversial data whether PCSK9 also regulates the levels of ApoER2 and VLDLR in vivo possibly affecting a wide range of neuronal functions [7, 10, 11]. In neurons, VLDLR and ApoER2 are involved in multiple cell signaling cascades through several extra- and intracellular binding partners including Reelin, apolipoprotein E (ApoE), disabled-1 (Dab1) and c-Jun N-terminal kinase (JNK) interacting proteins 1/2 (JIP1/2) among others (reviewed in ). Reelin and ApoE bind to and activate ApoER2 and VLDLR, controlling cortical and cerebellar development [13, 14], promoting cell survival , and regulating N-methyl-d-aspartic acid (NMDA) receptor activity through phosphorylation [16, 17]. Recently, it has been shown that PCSK9 reduces LDLR levels in mouse brain in vivo during development and after ischemic stroke , but the effect on ApoER2 and VLDLR remains unexplored.
The cerebellum displays strong expression of PCSK9, VLDLR and ApoER2, but little expression of LDLR  during postnatal development, coinciding with the developmental elimination of cerebellar granule neurons (CGN). The knockdown of both VLDLR and ApoER2 cause a Reeler-phenotype in mice, resulting in neuronal lamination defects in both the cortex and cerebellum . Proprotein convertase subtilisin/kexin type 9 has also been shown to play a role in neuronal development . In zebrafish, PCSK9 knockdown causes a severe disorganization of the CNS resulting in prenatal death . However, gene targeting of PCSK9 in mice results in lowered circulating lipoprotein and cholesterol levels with no gross effects on CNS development , similar to the phenotype observed in human populations with PCSK9 loss-of-function mutations .
The role of PCSK9 in neuronal apoptosis has been investigated in CGN cultures, where the transient expression of PCSK9 and its various mutants caused apoptosis partially reversible by caspase inhibitors . A recent study showed that PCSK9 is also involved in human umbilical vein endothelial cell (HUVEC) apoptosis through modulation of the intrinsic apoptotic pathway, and that knockdown of endogenous PCSK9 provides protection from apoptosis as shown by reduced caspase activity . The exact mechanism of PCSK9 action in mediating apoptosis is yet to be resolved.
In our studies, we used lentiviral delivery of short hairpin RNA (shRNA) to knock down the endogenous expression of PCSK9 in murine CGN prior to apoptosis induction by withdrawal of potassium, a well-characterized model of developmental neuronal apoptosis . Proprotein convertase subtilisin/kexin type 9 RNA interference (RNAi) increased the viability of CGN and reduced the extent of apoptosis, as quantitated by markers of apoptotic cell death: cleaved caspase-3 and nuclear condensation. The activation of c-Jun was also significantly diminished in PCSK9 RNAi CGN, suggesting the involvement of the JNK pathway. The protected cells also exhibited higher levels of ApoER2 post-deprivation with little effect on VLDLR levels, indicating a possible role for ApoER2 receptor signaling in PCSK9-dependent apoptosis. RNAi of ApoER2 was sufficient to reverse the protection mediated by PCSK9 RNAi. Pharmacological analysis revealed that NMDA receptor function, a known target of ApoER2 signaling, is not required for anti-apoptotic effects of PCSK9 RNAi. Instead, extracellular-regulated kinase (ERK) and JNK signaling pathways act in cooperation with PCSK9 to regulate c-Jun and caspase-3 activation during activity-dependent CGN apoptosis. Similar anti-apoptotic effects were also observed in staurosporine (STS)-induced CGN cell death model and nerve growth factor (NGF) deprivation of dorsal root ganglia (DRG) neurons. We conclude that PCSK9 regulates neuronal apoptosis through modulation of ApoER2 levels and related signaling pathways that control the activation of c-Jun and caspase-3, key factors that ultimately determine the onset of apoptosis in neurons.
Materials and methods
Stable HEK-293/mPCSK9-Fc cell line production
HEK-293 cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10 % FBS, 2 mM l-glutamine, 1 % penicillin, and 1 % streptomycin. Murine PCSK9 (mPCSK9) was cloned into the pIG (+) plasmid (R&D Systems) in-frame with a C-terminal Fc tag. pIG (+)-mPCSK9 was transfected to HEK-293 cells and stable cell lines were selected using G418. Single cell clones were generated and selected based on expression of mPCSK9-Fc using anti-human Fc antibody (Dako P214, 1:5,000).
RNAi and lentivirus production
Short hairpin RNA clones from the TRC-Mm1.0 (Mouse) library were acquired from OpenBiosystems (Thermo Fisher Scientific). Short hairpin RNAs were expressed from lentiviral pLKO.1 plasmid under the CMV promoter. Five shRNA clones targeting PCSK9 (clones TRCN0000032784-G1, TRCN0000032785-G2, TRCN0000032786-G3, TRCN0000032787-F11, TRCN0000032788-F12), ApoER2 (clones TRCN0000176508, TRCN0000177833, TRCN0000178706, TRCN0000176636, TRCN0000177656), VLDLR (clones TRCN0000127069, TRCN0000127070, TRCN0000127071, TRCN0000127072, TRCN0000127073), and a single control shRNA were used in this study. Lentiviral particles were produced from the selected clones, and an additional mPCSK9-Fc overexpression plasmid, by cotransfection of the selected plasmids together with the envelope plasmid pMD2.G and the packaging plasmid pPAX2 into human embryonic kidney cells (HEK-293T) using Fugene HD (Sigma) transfection reagent. After 48 h post-transfection, the supernatant containing the viral particles was collected, cleared by centrifugation, and concentrated for use in transduction of cultured neurons. After viral harvest, the cells were eradicated according to viral safety regulations.
Primers were designed in Geneious software and synthesized by oligomer (Helsinki, Finland) for assessment of mPCSK9, VLDLR, ApoER2, and GAPDH mRNA. The oligos used were: mPCSK9 (forward) 5′-CTGCTCCAGAGGTCATCACAGTC-3′; (reverse) 5′-CAGGGAACCAGGCCATGTTGATG-3′; VLDLR (forward) 5′-GTGCAGCTGGGTTTGAACTGATAGATAGG-3′; (reverse) 5′-GTCTTAGAAGCCGCATCAGTCCAGTAG-3′; ApoER2 (forward) 5′-GACGAGGACGACTGCCCCAA-3′; (reverse) 5′-GTCCCATCCCCACACTGGAACTC-3′; GAPDH (forward) 5′-ACCCCTTCATTGACCTCAACTACATGG-3′; (reverse) 5′-ATCCACAGTCTTCTGGGTGGCA-3′. RNA was extracted from cell lysates by RNeasy RNA extraction kit (Qiagen) as described in the manual. cDNA synthesis was done using dT-oligos with the Finnzymes Dynazyme cDNA synthesis kit (F470) immediately after RNA extraction or after storage of the RNA samples in −80 °C. PCR reactions were performed using Dynazyme II DNA polymerase. Samples run on the agarose gel were imaged by AlphaImager HP system.
Cerebellar granule neuron cultures and lentiviral transduction
Cerebellar granule neurons were prepared from P6 to P8 NMRI-mice. Mice were euthanized by decapitation, and the brain removed and placed in cold dissection buffer, composed of PBS supplemented with 0.25 % glucose, 0.3 % bovine serum albumin (BSA), 0.038 % MgSO4. Cerebella were cleaned and trypsinized in 10 ml of dissection buffer containing 0.025 % trypsin for 15 min in a 37 °C waterbath with occasional inversion. Prewarmed dissection buffer containing 10 % fetal bovine serum (FBS) and 12 μg/ml DNase I was added for DNA digestion and trypsin inactivation. Cells were washed in dissection buffer containing 0.012 % CaCl2, counted and plated on poly-l-lysine (Sigma)-coated cell culture plates at a density of 1–1.5 million cells per well in 6-well plates. Each well also included one sterile and poly-l-lysine coated 9 mm coverslip for immunofluorescence (IF) staining. Cells were resuspended and grown in neurobasal medium (Gibco) supplemented with 2 % B27, 2 mM l-glutamine, 1 % penicillin/streptomycin, 0.5 % FBS and 25 mM KCl. Half of the media was changed at 1 day(s) in vitro (DIV) and at 3–4 DIV prior to lentiviral transduction. Cerebellar granule neurons were transduced at 3–4 DIV and cultured for 72–96 h prior to treatments.
Dorsal root ganglion dissection, culture and NGF deprivation
Dorsal root ganglia (DRG) were collected from E15 NMRI mice and treated with 1.25 mg/ml trypsin (Worthington) in HBSS for 30 min at 37 °C. Then, the ganglia were washed twice with HBSS and treated with DNase I (40 μg/ml) in the presence of 3 mM MgCl2 in HBSS for 5 min at 37 °C. The DRG were washed with HBSS once and dissociated by trituration, using a silicone-treated Pasteur pipette. The cells were pelleted by centrifugation, resuspended in DMEM, 5 % FBS, and 1 % penicillin/streptomycin, and plated on an uncoated cell-culture dish for 5 h at 37 °C, in 5 % CO2 to reduce the number of non-neuronal cells, which attach to uncoated plastic. The medium, enriched with dorsal root ganglion neurons (DRGN), was then collected, the cells pelleted by centrifugation and resuspended in neurobasal medium, supplemented with 2 % B-27, 0.2 % Primocin and 20 ng/ml NGF (Promega). The cells were plated in a drop of medium to MatTek cell-culture dishes previously coated with 1 mg/ml poly-l-ornithine (Sigma) diluted in 0.15 M borate buffer pH 8.7, and 40 ug/ml Laminin (Sigma) diluted in HBSS. More of the same medium was added next morning to cover the whole dish. Half of the medium was changed at least 2 h before lentiviral transduction at 10 DIV. Dorsal root ganglion neurons were transduced for 72 h prior to NGF deprivation at 13 DIV. For NGF deprivation, cells were washed twice with plain Neurobasal, and 1 ml of neurobasal supplemented with 2 % B-27, 1 % penicillin, 1 % streptomycin, and 0.5 μg/ml anti-NGF antibody (Millipore) was added to cells for 24 h. Cells were fixed using 4 % PFA, the axons stained with anti-β-III-tubulin (TUJ1) antibody and imaged using a confocal microscope (Carl Zeiss LSM 5). Axons were quantitated from microscope images by counting the number of intact axons showing no blebbing or fragmentation crossing the diagonal of the image.
Cerebellar granule neuron deprivations were performed in 6–7 DIV cultures. Cells were washed twice with plain neurobasal and neurobasal with 0.5 % FBS, 1 % penicillin/streptomycin, 2 mM l-glutamine and 5 mM KCl concentration was used to deprive the cells. For pharmacological inhibition, cells were pre-treated with inhibitors for 30 min and equal concentration of inhibitors was added to the deprivation media. Deprivation was stopped by the collection of the conditioned media and cell lysate. Staurosporine (500 nM; Sigma) induced apoptosis was assessed after 6 or 24 h. The inhibitors used were wortmannin (100 nM; Sigma), U0126 (10 μM; Sigma), SP600125 (4 μM; Sigma), Sulfasalazine (125 μM; Santa Cruz), and PP2 (8 μM; Santa Cruz). NMDAR antagonists AP5 (Sigma) and MK-801 (Sigma) were used at concentrations of 50 and 0.5 μM, respectively.
Protein samples and western blotting
The cell lysate collection procedure was done on ice. Protein lysates were scraped in extraction buffer containing 10 mM Tris–HCl, pH 7.6, 2 mM EDTA, 0.15 M NaCl, 1 % Triton-X, inhibitor cocktail (1 pill/10 ml; Roche), and 0.25 % NP-40 (Sigma). Lysates were incubated for 30 min on ice and cleared by centrifugation at 10,000g for 10 min. Lysate concentrations were measured with BCA protein concentration kit (Pierce) and equal protein amounts (20–40 μg per lane) were loaded on the gel. Samples were denatured for 10 min at 70 °C and reduced with 1 % β-mercaptoethanol (BME) in the 10 μl of 4× loading buffer (Invitrogen) added to each sample. The gel apparatus (X-Cell SureLock™; Invitrogen) was assembled with NuPAGE 4–12 % 10-well Bis–Tris gels (Invitrogen) immersed in running buffer (Invitrogen). Protein ladders from Bio-Rad (Precision Plus Kaleidoscope, 161-0375) and Invitrogen (Novex Sharp Pre-Stained, LC5800) were used as standards for protein size assessment. Gels were run at 160 V for 60 min with a Bio-Rad power source. Prior to semi-dry blotting (Semi-Dry Trans-Blot SD; Bio-Rad), the gel and the PVDF protein membrane (Amersham Hybond-P) were pre-soaked in the transfer buffer (48 mM Tris, 39 mM glycine, 13 mM SDS, 200 ml methanol, and 1 l of reverse osmosis water) for 15 min. Proteins were transferred to the membrane at 20 V for 30 min.
Membranes were blocked in 5 % non-fat milk powder (Valio) diluted in TBST [TBS + 0.1 % Tween-20 (Sigma)] for 1 h on a gyro-rocker (Stuart, SLL3) at room temperature (RT). Membranes were washed with plain TBST 3 × 10 min before addition of primary antibody (1Ab) for overnight incubation at 4 °C on a rocker. Primary antibodies used were: cleaved caspase-3 (Cell Signaling; rabbit, 1:1,000), β-tubulin I + II (Sigma; mouse, 1:1,000), phospho-c-Jun (Cell Signaling; rabbit, 1:1,000), ApoER2 (Sigma; rabbit, 1:2,000), VLDLR (Santa Cruz; rabbit, 1:500), and GAPDH (Millipore; mouse, 1:1,000). After overnight 1Ab incubation, membranes were washed three times 10 min with TBST and appropriate secondary antibody (2Ab) was added for 1 h on the gyro-rocker at RT. Horseradish peroxidase-linked anti-mouse (GE Healthcare) and anti-rabbit (GE Healthcare) secondary antibodies were used at a 1:6,000 dilution in TBST. Membranes were washed 3× 10 min with TBST and then soaked for 3 min with Pierce ECL reagent (Thermo Scientific). Protein bands were detected with LAS-3000 imaging system (Fujifilm). Quantity One® software (Bio-Rad) was used for optical density quantitation of western blots. Membranes were reprobed with several antibodies and stripped between probings. Membrane stripping was done at 55 °C for 20 min in stripping buffer (20 ml 3 M Tris–HCl pH 6.8, 100 ml 20 % SDS, 0.75 % β-mercaptoethanol). The membranes were then washed 3× 15 min with TBST before another cycle of blocking—1Ab—2Ab—detection.
Cells grown on poly-l-lysine coated coverslips were fixed for 20 min with 4 % PFA in PBS. Cells were washed three times with PBS before adding blocking buffer [5 % normal serum (goat and/or donkey), 1 % BSA, 0.1 % gelatin, 0.1 % Triton-X, 0.05 % Tween-20] for 1 h at RT. Primary antibodies were added into dilution buffer (1 % BSA, 0.1 % gelatin) and incubated overnight at +4 °C. Cells were washed three times with PBS and secondary antibodies diluted into PBS were added for 1 h in RT protected from light. Cells were washed twice with PBS and cells stained with Hoechst (1:10,000) for 10 min at RT. Cells were washed twice with PBS and once with milli-Q water to remove excess salts. Coverslips were mounted on microscope slides with ProLong anti-fade reagent (Invitrogen) and sealed with nail polish. The primary antibodies used were Tuj1 (Covance; rabbit, 1:500), MAP2 (Sigma; mouse, 1:500) and phospho-c-Jun (Cell Signaling; rabbit, 1:250). Secondary antibodies used were AlexaFluor-conjugated antibodies (Invitrogen) 488-goat-anti-mouse, 488-donkey-anti-rabbit, 568-goat-anti-mouse and 568-donkey-anti-rabbit at 1:2,000 dilutions. ImageJ software was used for cell counting and GraphPad Prism and Adobe Photoshop for preparation of figures.
Minimum of three repetitions from at least two different batches of cells were analyzed for each experiment. Microsoft Excel and GraphPad Prism software were used for statistical analyses. Statistical significance was evaluated with Student’s t test or ANOVA, with the significance threshold set at p < 0.05.
PCSK9 RNAi inhibits caspase-3 and c-Jun activation in potassium deprived CGN
We used lentiviral RNAi to reduce the endogenous expression of PCSK9 to assess its role in potassium (K5) deprivation-induced apoptosis in murine CGN, a well-characterized neuronal apoptosis model . Replacing the depolarizing 25 mM KCl-containing medium with 5 mM KCl medium results in a rapid apoptotic death of CGN mimicking the developmental elimination of cerebellar neurons [24, 25]. The point-of-no-return for the CGN apoptosis takes place within the first 6 h of deprivation, and the onset of apoptosis can be observed at 6 h post-deprivation by phosphorylation of c-Jun, the central transcription factor required for JNK-dependent apoptosis, and activation of caspase-3, a major executioner of apoptosis [22, 26, 27]. Although an increase in PCSK9 expression coincides with CGN apoptosis, its role in the process is currently poorly understood .
We then assessed the effect of PCSK9 RNAi on the apoptosis induced by K5 deprivation. We found that PCSK9 RNAi reduced the activation of phospho-c-Jun and caspase-3 as quantitated by WB (Fig. 1e–h) after 6 h K5 deprivation. An additional PCSK9 RNAi construct (F12) and a non-target control shRNA sequence (Ctrl shRNA) were included to control for the possible off-target effects resulting from lentiviral RNAi. PCSK9 RNAi constructs G2 and F12 reduced caspase-3 activity by 58.7 ± 4.8 and 44.0 ± 5.3 % respectively; and phospho-c-Jun activity by 44.4 ± 11.5 and 44.5 ± 10.2 %, respectively, whereas Ctrl shRNA only slightly increased their respective activities in comparison to the control cells (Fig. 1g, h).
Phosphorylation of c-Jun and caspase-3 cleavage precede apoptosis and are inhibited by PCSK9 RNAi
Similar results were obtained by microscopic quantitation of phospho-c-Jun positive cells and apoptotic nuclei (Fig. 2e–h). PCSK9 RNAi cells showed both increased cell viability and decreased number of phospho-c-Jun positive cells at timepoints ranging from 4 to 24 h and 0 to 9 h, respectively (Fig. 2g, h). Immunofluorescence imaging of CGN showed that active phospho-c-Jun colocalizes with the cell nuclei and precedes nuclear condensation (Fig. 2f). Cell nuclei were scored according to their morphology and phospho-c-Jun positivity (Fig. 2g, h). In control K5 cells, 79.9 ± 2.1 % of healthy nuclei showing no signs of condensation or fragmentation were phospho-c-Jun positive, compared to PCSK9 RNAi cells, which showed only 39.1 ± 5.4 % positivity at 6 h K5, without a significant increase to control cells cultured in K25 (Fig. 2g). The basal level of phospho-c-Jun positivity in K25 cells was also decreased by PCSK9 RNAi (Fig. 2e, g). While the total number of neurons present in the culture did not significantly differ between the groups (data not shown), after 6 h K5 deprivation, 33.6 ± 3.1 % of control cells showed apoptotic nuclear morphology but only 19.9 ± 2.4 % of PCSK9 RNAi K5 cells were apoptotic, a reduction of 41 % (Fig. 2h). The protective effect of PCSK9 RNAi was still seen at 24 h post-deprivation, as only 27.4 ± 7.2 % of control cells were viable compared to the 43.4 ± 6.9 % of viable PCSK9 RNAi cells (Fig. 2h). However, even in the PCSK9 RNAi, CGN survival was reduced by 24 h, possibly due to activation of other, non-apoptotic cell death pathways .
Reduction of active c-Jun suggests that PCSK9 RNAi mediates its protective effect by modulating the JNK-pathway upstream of c-Jun and caspase-3 activation, which are known effectors of potassium deprivation in CGN. Also, the basal level of c-Jun activation was lowered in K25 PCSK9 RNAi cells (Fig. 2b, e, g). Altogether, these findings show that PCSK9 RNAi is neuroprotective against K5 deprivation-induced apoptosis in CGN and that this process involves modulation of c-Jun activation.
Cells protected by PCSK9 RNAi exhibit altered levels of lipoprotein receptors VLDLR and ApoER2
To study the role of ApoER2 and VLDLR in the neuronal survival further, we produced lentiviral RNAi against both receptors. Efficiency of VLDLR and ApoER2 RNAi was quantitated by WB and RT-PCR (Suppl. Fig. 1). This also validated the specificity of the VLDLR and ApoER2 antibodies used in this study. Two RNAi constructs displaying ability to decrease lipoprotein receptor levels were chosen and their effects were assessed in PCSK9 RNAi-treated CGN undergoing 6 h K5 deprivation. Importantly, the knockdown of ApoER2 alone (or both of the receptors) simultaneously with PCSK9 RNAi was able to completely reverse the protection elicited by PCSK9 RNAi, as assessed by caspase-3 activation (Fig. 3e, f). Very low density lipoprotein receptor RNAi alone did not have any reversal effect, although it should be noted that the efficacy of the VLDLR RNAi was somewhat weaker as compared to ApoER2 RNAi (Suppl. Fig. 1).
Very low density lipoprotein receptor is located in the fluid, phospholipid-rich regions of the membrane and is primarily involved in the internalization of lipoprotein particles consisting of ApoE and other lipoproteins as well as Reelin. In comparison, ApoER2 is mostly located in lipid-rafts and functions primarily in cell signaling and as a scaffold for intracellular adaptor molecules . Apolipoprotein receptor 2 has been shown to regulate neuronal survival in the brain via a JNK-dependent mechanism involving the adaptor molecule JIP1/2, suggesting a possible mechanism for PCSK9 RNAi-mediated protection . Therefore, increased levels of ApoER2 are likely the key contributor to the anti-apoptotic effects of PCSK9 RNAi.
NMDA receptor activity is not required for the anti-apoptotic effects of PCSK9 RNAi
Src family kinases are important downstream effectors of neuronal ApoER2/VLDLR signaling, and can enhance NMDA receptor activity via subunit tyrosine phosphorylation [17, 34]. PP2, a selective inhibitor of SFKs, had no effect on anti-apoptotic effects of PCSK9 RNAi as measured by caspase-3 activation at 6 h post-deprivation (Fig. 4b). Therefore, we conclude that NMDAR modulation is not mechanistically involved in PCSK9 RNAi neuroprotection, at least in this CGN model.
Pharmacological profiling of neuroprotection elicited by PCSK9 RNAi
In order to dissect potential pathways associated with PCSK9 RNAi-mediated neuroprotection, we assessed the involvement of selected intracellular signaling routes, previously linked with ApoER2/VLDLR signaling or potassium deprivation-induced CGN apoptosis, in the anti-apoptotic effects of PCSK9 RNAi by pharmacological modulation. We used inhibitors wortmannin (Wrt), U0126, SP600125 and sulfasalazine (SFS) to block phosphatidylinositol 3-kinase (PI3K), ERK, JNK, and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) pathways, respectively. JNK and ERK are mitogen-activated protein kinases (MAPKs), with diverse roles in the regulation of cell death and survival depending on the cell type and developmental stage [26, 35].
PI3K/Akt and NF-κB pathways have previously been shown to be critical for CGN survival [37, 38]. Inhibition of PI3K or NF-κB in control cells with K5 deprivation resulted in enhanced caspase-3 activation (Fig. 5c, d) [38, 39]. When Wrt or SFS were added to PCSK9 RNAi CGN, the anti-apoptotic effects were partially reversed. However, these effects were weaker when compared to the reversal elicited by ApoER2 RNAi (Fig. 3e, f). Altogether, these data suggest that multiple signaling pathways contribute to neuroprotection elicited by PCSK9 RNAi.
The role of PCSK9 in other models of neuronal apoptosis
We also assessed axonal degeneration in a dissociated DRGN culture induced by NGF-withdrawal. Axonal degeneration in DRGN has been previously shown to be partially JNK-dependent [41, 42]. Moreover, DRGN express lipoprotein receptors LDLR and ApoER2 . Dorsal root ganglion neurons grow extensive axonal networks in culture with a relatively small number of neuronal cells and a high number of proliferating glial cells. Counting the number of intact, non-blebbing axons crossing the diagonal of the image was used to score axonal degeneration (Fig. 6d). In control cells, 59.8 ± 5.8 % of axons remained intact after 48 h NGF-deprivation whereas PCSK9 RNAi increased the intact portion of neurites up to 77.7 ± 9.3 % (Fig. 6e), an increase of 30 %. Altogether, these data suggest that PCSK9 may modulate apoptotic processes involving multiple signaling pathways in different models of neuronal death and degeneration.
Proprotein convertase subtilisin/kexin type 9 has a poorly characterized physiological role in neuronal apoptosis and in the modulation of lipoprotein receptors VLDLR and ApoER2 in the brain. PCSK9 is known to bind to both receptors via the EGF-A repeat of their ectodomains and to target them for degradation, while the expression of PCSK9 can be induced by apoptotic stimulus together with known apoptosis mediators such as death receptor-6 and caspase-3 [4, 44]. Recently, PCSK9 was shown to be upregulated and to control LDLR levels in ischemic brain . If PCSK9, with its numerous naturally occurring gain-of-function and loss-of-function polymorphisms, also controls ApoER2 and VLDLR levels in the adult brain after apoptotic insults, the possible consequences for neuronal function and integrity may be profound.
In this study, we aimed at preliminary characterization of PCSK9 action in the apoptotic processes of several neuronal death models: activity-dependent and staurosporine-induced CGN apoptosis, as well as NGF deprivation-induced axonal degeneration in dissociated DRGN cultures. We produced lentiviral tools encoding shRNAs targeting PCSK9, ApoER2, and VLDLR. Recently, a similar approach was taken to elucidate the role of PCSK9 in HUVEC apoptosis . We have shown that PCSK9 RNAi significantly reduced cell death in the potassium-deprived or STS-treated CGN, and axonal degeneration in NGF-deprived DRGN, showing that PCSK9 has a strong capacity to modulate all these different neuronal death pathways.
Very low density lipoprotein receptor and ApoER2-mediated signaling might provide the basis for the neuroprotection elicited by PCSK9 knockdown. Our results show that, in potassium-deprived CGN, VLDLR and ApoER2 are depleted, and most likely this is related to the upregulation of PCSK9 . This depletion would then reduce the activity of several critical survival signaling pathways. We found that PCSK9 RNAi resulted in elevated levels of ApoER2 with less effect on VLDLR levels. Based on our current data, we cannot address the reason for this differential effect. Both extracellular and intracellular routes for PCSK9-dependent lipoprotein degradative action have been proposed [45, 46]; however, the current study was not designed to address these questions. Moreover, it is possible that PCSK9-independent mechanisms of lipoprotein receptor degradation, mediated, e.g., by ubiquitination , may be differentially regulating receptor degradation in stressed and apoptotic neurons. Importantly, only the knockdown of ApoER2 but not of VLDLR was able to completely reverse the anti-apoptotic effect of PCSK9 RNAi, suggesting that ApoER2 is the key mediator of these effects.
There is an emerging view of lipoprotein receptors serving as important players in neuronal survival signaling . Therefore, PCSK9 would be an ideal tool for neurons to quickly downregulate these survival signals to achieve rapid and coordinated apoptosis. This may explain the increased expression of PCSK9 in the postnatal cerebellum that coincides with the extensive developmental apoptosis. However, although PCSK9 knockdown in zebrafish resulted in severe disorganization of the CNS , no gross alterations in the organization of the cortex and cerebellar layers were found in PCSK9−/− mice . If the sole function of PCSK9 in the postnatal mammalian cerebellar neurons is rapid downregulation of ApoER2-dependent survival signaling, it is likely that there are compensatory proapoptotic mechanism(s) that could overcome the lack of PCSK9 to ensure proper cerebellar development. In this regard, it should be noted that PCSK9 might regulate cell death responses differentially in different cell types. In HepG2 cells, PCSK9 gain-of-function mutation (D374Y) was associated with reduced stress responses and cell death . However, these authors also concluded that the PCSK9 function related to apoptosis might be different in hepatocytes and cerebellar neurons.
To explore the signaling pathways involved in PCSK9 RNAi-related neuroprotection, we used a panel of pharmacological inhibitors to block known apoptotic and survival pathways in an attempt to reverse the protective effect. Based on these data, we suggest that PCSK9 may associate with multiple pro- and anti-apoptotic signaling pathways, mostly associated with ApoER2 function. Reduced PCSK9 levels and inhibition of either JNK or ERK pathways had additive anti-apoptotic effects, while inhibition of PI3K or NF-κB partially reversed the anti-apoptotic effects of PCSK9 RNAi. Considering the prosurvival effects of physiological NMDA currents and the potent NMDA receptor enhancing effects of ApoER2 signaling [34, 51], it was surprising that interfering with NMDA receptor function or SFK activity had no effect on the anti-apoptotic effects of PCSK9 RNAi.
It is plausible that the upregulation of PCSK9 in the degenerating, aging, or otherwise traumatized brain tissue could compromise neuronal survival by exploiting the mechanisms identified in this work. Moreover, ApoE plays a critical role in the pathophysiology of Alzheimer’s disease (AD) , and altered lipoprotein receptor signaling may contribute to disease progression by modulating, e.g., β-amyloid peptide (Aβ)-induced synaptic dysfunction  or neuronal cell death in general . In this regard, it is interesting to note that PCSK9 was recently reported to be upregulated in the dentate gyrus following ischaemic stroke . To date, only one published study exists addressing the potential genetic link of PCSK9 to neurodegenerative diseases and it found no association of two PCSK9 polymorphisms to sporadic AD in a Japanese cohort . Given the important role of apoptosis in both developing and degenerating nervous system, further studies are required to understand if, how, and when PCSK9 is upregulated in the aging and degenerating brain, but also if the common PCSK9 polymorphisms are associated with neuronal disease. There is increasing interest towards developing ApoE-based therapeutics for AD , and PCSK9 inhibitors for hypercholesterolemia . Thus, more detailed understanding of the potential roles of PCSK9 in regulation of neuronal cell death will support the development of safe and efficacious therapeutic strategies targeting ApoE and lipoprotein receptor function.
This study was supported by grants from the Academy of Finland (grant numbers 281081 and 126889), Sigrid Jusélius Foundation, Biocentrum Helsinki, Finnish Cultural Foundation and Antti and Jenny Wihuri Foundation. The research leading to these results has received funding from the European Union’s Seventh Framework Programme (FP7/2007–2011) under grant agreement No. 206918 and Academy of Finland program 11186236 (Finnish Centre of Excellence Program 2008–2013). K.K. and H.J.H. designed research; K.K., P.M., and K.M. performed research; K.K., U.A., and H.J.H. analyzed data; and K.K., U.A., and H.J.H. wrote the paper. H.J.H is a cofounder, employee and shareholder of Hermo Pharma Ltd. Other authors declare that they have no conflict of interest.